Brokers Issue Forecasts for Neurocrine Biosciences, Inc.’s FY2025 Earnings (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at Leerink Partnrs raised their FY2025 earnings estimates for Neurocrine Biosciences in a research report issued on Wednesday, May 1st. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of $6.90 per share for the year, up from their prior estimate of $6.65. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.78 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences’ FY2026 earnings at $9.30 EPS, FY2027 earnings at $10.90 EPS and FY2028 earnings at $12.40 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. The company’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.88 EPS.

Other equities analysts have also recently issued reports about the company. Wells Fargo & Company upgraded Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $140.00 to $170.00 in a research note on Wednesday, April 24th. HC Wainwright boosted their price objective on shares of Neurocrine Biosciences from $150.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday. The Goldman Sachs Group raised their target price on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. Wedbush reaffirmed an “outperform” rating and set a $147.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, April 17th. Finally, Citigroup increased their price target on Neurocrine Biosciences from $140.00 to $150.00 and gave the stock a “neutral” rating in a research report on Friday. Six analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $147.88.

Neurocrine Biosciences Stock Up 0.6 %

Shares of NASDAQ NBIX opened at $140.71 on Monday. The stock’s 50 day moving average price is $137.37 and its two-hundred day moving average price is $129.00. Neurocrine Biosciences has a 52-week low of $89.04 and a 52-week high of $148.37. The stock has a market capitalization of $14.16 billion, a P/E ratio of 38.76 and a beta of 0.28.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds have recently bought and sold shares of NBIX. FCF Advisors LLC purchased a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at approximately $1,157,000. abrdn plc grew its holdings in shares of Neurocrine Biosciences by 2,503.0% during the fourth quarter. abrdn plc now owns 83,633 shares of the company’s stock valued at $11,019,000 after buying an additional 80,420 shares in the last quarter. Redhawk Wealth Advisors Inc. acquired a new position in Neurocrine Biosciences during the fourth quarter valued at $1,245,000. HealthInvest Partners AB purchased a new stake in Neurocrine Biosciences in the 4th quarter worth about $1,662,000. Finally, Roman Butler Fullerton & Co. purchased a new stake in Neurocrine Biosciences in the 4th quarter worth about $1,256,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider David W. Boyer sold 1,328 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $135.41, for a total transaction of $179,824.48. Following the completion of the sale, the insider now directly owns 4,895 shares in the company, valued at $662,831.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, insider David W. Boyer sold 1,328 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $135.41, for a total transaction of $179,824.48. Following the completion of the sale, the insider now directly owns 4,895 shares of the company’s stock, valued at approximately $662,831.95. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider David W. Boyer sold 456 shares of Neurocrine Biosciences stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total value of $64,733.76. Following the completion of the transaction, the insider now owns 4,894 shares in the company, valued at $694,752.24. The disclosure for this sale can be found here. In the last three months, insiders sold 181,547 shares of company stock valued at $25,039,887. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.